tag:blogger.com,1999:blog-5574479.post5907789356126228380..comments2018-02-22T05:00:43.369+00:00Comments on The IPKat: Feeling fine? Europe enriched by AstraZeneca's millionsRosie Burbidgehttp://www.blogger.com/profile/04620450399931331172noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-5574479.post-74579481373385024102012-12-08T21:51:38.357+00:002012-12-08T21:51:38.357+00:00&quot;threatening to shut down research institutes...&quot;threatening to shut down research institutes&quot;<br /><br />Such veil threats will never come to fruition. Well, not now there&#39;s so few left after numerous closures in the last few years.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-5574479.post-73479524582736443272012-12-06T11:24:42.148+00:002012-12-06T11:24:42.148+00:00Presumably the Kat&#39;s comments on investing in ...Presumably the Kat&#39;s comments on investing in generics is meant to be slightly mischievous (I hope your insurance covers giving financial advice!). I think for now the big pharma companies remain very good investments.<br /><br />Fining big pharma companies is an interesting topic as I think US authorities are openly questioning whether it really does cause any change in their behaviour. Big pharma seem to be playing an interesting game of brinkmanship with US and European governments, threatening to shut down research facilities in response to increased regulation by government authorities and pressures to decrease prices. For now though the US govt and EU institutions remain more powerful and big pharma need to start realising that.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-5574479.post-47168902660852070062012-12-06T10:56:32.542+00:002012-12-06T10:56:32.542+00:00&quot;Another advantage of backing the generics is...&quot;Another advantage of backing the generics is that they are unlikely to find themselves in trouble with the Commission for eliminating competition, so long as they play by the fairly pro-generic rules which have been established for their benefit.&quot;<br /><br />Er, what planet is this Kat on? Which particular &quot;pro-generic&quot; rules are you referring to, and in which way have they been established for the benefit of generic companies?<br /><br />If you are simply referring to the fact that, as soon as patents expire for a particular pharmaceutical product, the door is opened for generic competition, then where&#39;s the problem? However, I infer from the tone of your comment that you were hinting at something more. <br /><br />Please enlighten us. Anonymousnoreply@blogger.com